Rahul D. Ballal, CEO: Enliven Therapeutics ELVN Sell · Filed 23/02/22

Trade details

Type: Insider sale
Amount: $153,132.26
Shares · price: 32,861 sh · $4.66 a share
Held after: 87,835 sh
Stock: Enliven Therapeutics ELVN
Person: Rahul D. BallalCEO
Trade date: 23/02/22
Filed: 23/02/22
Days to filing: 0 days

Sold 27.2% of holdings

Share of holding sold: 27.2%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 23/01/23~23/03/24

Rahul D. Ballal's recent trades

Rahul D. BallalDirector
Sell10b5-1 planAgios Pharmaceuticals
Sell10b5-1 plan
Agios Pharmaceuticals
AGIO
$433.6K
8,132 sh
$433.6K
Filed 24/11/12
Traded 24/11/07
Rahul D. BallalDirector
Sell10b5-1 planAgios Pharmaceuticals
Sell10b5-1 plan
Agios Pharmaceuticals
AGIO
$288.7K
4,929 sh
$288.7K
Filed 24/11/12
Traded 24/11/08
Rahul D. BallalDirector
Sell10b5-1 planAgios Pharmaceuticals
Sell10b5-1 plan
Agios Pharmaceuticals
AGIO
$204.4K
3,571 sh
$204.4K
Filed 24/11/12
Traded 24/11/08
Rahul D. BallalDirector
Sell10b5-1 planAgios Pharmaceuticals
Sell10b5-1 plan
Agios Pharmaceuticals
AGIO
$101.6K
1,868 sh
$101.6K
Filed 24/11/12
Traded 24/11/07
Rahul D. BallalDirector
Sell10b5-1 planAgios Pharmaceuticals
Sell10b5-1 plan
Agios Pharmaceuticals
AGIO
$88.8K
1,500 sh
$88.8K
Filed 24/11/12
Traded 24/11/08